AACC 2019 - Companies Involved in the Development and Manufacturing of Diagnostic Tests

In my last post I showed the breakdown of countries represented at the AACC’s Annual Scientific Meeting Clinical Lab Expo. In this post, I’ll dig a little deeper into those companies that focus on developing and manufacturing diagnostic tests. I’m using data I scraped from the AACC website using python and BeautifulSoup.

 Not surprisingly, the number of diagnostic testing companies comprise a majority of the companies exhibiting at AACC. There are 824 companies of all types exhibiting at AACC next week, with 588 companies or 71% in the diagnostic testing space. This is down just slightly from 2018 where 601 of the 814 companies exhibiting were in the diagnostic space.

The representation of countries and proportion of companies for diagnostic testing is similar for the overall expo:

AACC 2019

AACC 2019

And this is similar to how the expo looked last year:

AACC 2018

AACC 2018

Fortunately we can go further in our analysis because AACC allows exhibitors to provide subcategories for the diagnostic testing category. Additionally, companies could select as many subcategories in diagnostic testing which applied to them, so we can gain some insight into where there is overlap.

I created a heatmap by generating a co-occurrence matrix using the pandas library for python to help us hone in on the areas where there is a lot of activity. In particular, the areas of infectious disease testing, point of care testing, rapid tests, and molecular diagnostics light up the most:

Dx testing sub-categories 2019

Dx testing sub-categories 2019

So, what are the subcategories that overlap with infectious disease testing?

Not surprisingly, the top of the list includes rapid tests, point of care testing, and molecular diagnostics: 

Dx Testing Subcategories / Infectious Disease 2019

Dx Testing Subcategories / Infectious Disease 2019

Seeing rapid tests (like CLIA-waived lateral flow tests) and point of care testing having high co-occurrence with infectious disease testing makes sense as time to result is of utmost importance when treating patients with infectious conditions.

And seeing molecular diagnostics having high co-occurrence with infectious disease testing also makes sense as screening for colonization of highly pathogenic organisms and using molecular methods can help identify antimicrobial resistant organisms faster than traditional sensitivity testing.

We can also see some of the applications in the subcategories that have high co-occurrence with infectious disease testing, such as HIV, influenza, hepatitis, and STD testing. We also see a bit of overlap with cancer testing, most likely because the companies developing molecular testing platforms can uses these technologies for cancer diagnostic testing applications as well.

In my next post, we’ll take a closer look at point of care testing, rapid tests, and molecular diagnostics.

 

Are you going to AACC? Let us know!

 

 Stephanie Kreml, MD, Senior Advisor

Stephanie Kreml